Viewing Protocol Section

Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section


Ignite Creation Date: 2024-07-17 @ 10:52 AM
Last Modification Date: 2024-10-26 @ 3:33 PM
Study NCT ID: NCT06478719
Protocol Section: NCT06478719
Start Identification Module Data
Brief Title: To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
Official Title: A Phase III Randomized Double-blinded Study of FB-1603 to Evaluate the Safety and Efficacy in Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization FECHT Trial
Acronym: None
Organization: Febico Biomedical Corp
Organization Class: INDUSTRY
Organization Study ID: FB-1603_TACE_PII_2022_1
Start Status Module Data
Status Verified Date: 2024-06
Overall Status: RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Febico Biomedical Corp
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Febico Biomedical Corp
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload